Nicholas Pulliam
Eli Lilly (United States)(US)Loxo Oncology at Lilly (United States)(US)
Publications by Year
Research Areas
Cancer, Lipids, and Metabolism, Epigenetics and DNA Methylation, Immune cells in cancer, PARP inhibition in cancer therapy, BRCA gene mutations in cancer
Most-Cited Works
- → An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations(2018)126 cited
- → Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease(2016)75 cited
- → Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion(2018)22 cited
- → Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells(2019)17 cited
- → Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer(2015)9 cited
- → 41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model(2023)5 cited
- → Estrogen Receptor Regulation of MicroRNAs in Breast Cancer(2018)3 cited
- → Directed enzyme deposition via electroactive polymer-based nanomaterials for multi-analyte amperometric biosensors(2012)3 cited
- Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.(2016)